Autolus Therapeutics plc Cost of Revenue 2011-2026 | AUTL

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Quarterly Cost of Revenue Autolus Therapeutics plc

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
28.6 M	24.4 M	18 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
28.6 M	18 M	23.7 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	32.2 M	-	2.43 %	$ 254 M	Germany
Acasti Pharma ACST	76 K	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	100 K	-	-	$ 86.2 M	USA
Kamada Ltd. KMDA	73.3 M	$ 8.81	1.73 %	$ 260 M	Israel
I-Mab IMAB	27.2 M	-	-	$ 866 M	China
Evogene Ltd. EVGN	767 K	$ 0.81	-9.28 %	$ 27.9 M	Israel
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
Nymox Pharmaceutical Corporation NYMX	4 K	-	-19.68 %	$ 18.4 M	Canada
Albireo Pharma ALBO	1.36 M	-	-0.23 %	$ 916 M	USA
Aptorum Group Limited APM	421 K	$ 0.79	-1.29 %	$ 4.31 M	China
Ampio Pharmaceuticals AMPE	369 K	-	-11.43 %	$ 502 K	USA
Acorda Therapeutics ACOR	15.3 M	-	-24.86 %	$ 820 K	USA
Ascendis Pharma A/S ASND	3.52 M	$ 224.42	-2.52 %	$ 5 B	Danmark
Aeterna Zentaris AEZS	90 K	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
Aytu BioScience AYTU	20.6 M	$ 2.36	2.27 %	$ 14.8 M	USA
AstraZeneca PLC AZN	12.4 B	-	-	$ 96.9 B	Britain
Codexis CDXS	16.3 M	$ 1.17	-0.85 %	$ 85.9 M	USA
BioNTech SE BNTX	2.91 B	$ 110.12	-0.28 %	$ 27.2 B	Germany
Amneal Pharmaceuticals AMRX	1.77 B	$ 14.49	-0.75 %	$ 4.48 B	USA
AIkido Pharma AIKI	9 K	-	1.93 %	$ 17.4 M	USA
CureVac N.V. CVAC	238 M	-	-	$ 867 M	Germany